Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 3

Engineers uncover why tiny particles form clusters in turbulent air

Tiny solid particles—like pollutants, cloud droplets and medicine powders—form highly concentrated clusters in turbulent environments like smokestacks, clouds and pharmaceutical mixers.

What causes these extreme clusters—which make it more difficult to predict everything from the spread of wildfire smoke to finding the right combination of ingredients for more effective drugs—has puzzled scientists.

A University at Buffalo study, published in Proceedings of the National Academy of Sciences, suggests the answer lies within the electric forces between particles.

Psychedelic medicine could revolutionise how we treat mental illness

Depression, anxiety, PTSD and other maladies of the mind are plaguing our societies. Our medicines are now decades old, and their effectiveness is questionable. Around half of those taking antidepressants experience no benefits. Side effects are common, and relapse rates when stopping the pills can reach 80%.

If someone told you we have a remedy with nearly no relapse, no long term side effects, and life-altering potential, wouldn’t you be curious?

Enter Dr. Ayla Selamoglu (Newnham 2016). As a Trinity postdoc endorsed by biotechnologist Prof. Christopher Lowe OBE, her research centres on psychedelic medicine and drug development.

Psychedelic medicine has the potential to revolutionise psychiatry. And the revolution is starting here.

Dr. Ayla Selamoglu is an expert on psychedelic medicine. Her work shows how nature’s most mysterious compounds provide new ways to combat mental illness.

Continue reading “Psychedelic medicine could revolutionise how we treat mental illness” | >

Corstasis scores FDA nod for nasal spray treatment, touts sales potential

Forty-two years after approving the potent diuretic Bumex (bumetanide) as both an oral and infused treatment for edema, the FDA has endorsed a new version of the drug to be delivered as a nasal spr | Forty-two years after approving the potent diuretic Bumex (bumetanide) as both an oral and infused treatment for edema, the FDA has endorsed a new version of the drug to be delivered as a nasal spray. The U.S. regulator has signed off on Corstasis Therapeutics’ Enbumyst to relieve the edema associated with congestive heart failure, chronic kidney disease and liver disease.

A Shot of Sound: Gene Therapy Reverses Deafness in Just Weeks

Gene therapy has successfully reversed deafness in both children and adults by delivering a healthy gene directly to the ear. One injection led to rapid hearing recovery, especially in younger patients, with no serious side effects.

A single shot of gene therapy restored hearing in people born deaf, with most showing improvement within weeks and some regaining full function.

Differences in brain chemistry shape two common movement disorders

Researchers have identified a neurochemical signature that sets Parkinson’s disease apart from essential tremor — two of the most common movement disorders, but each linked to distinct changes in the brain.

In a new study in Nature Communications, scientists identified unique chemical signaling patterns of two key neurotransmitters — dopamine and serotonin — that distinguish these two disorders.

“This study builds on decades of work,” said a co-senior author, who with colleagues developed the multi-faceted technologies and the theoretical constructs for the work over their 15 years at the research institute.

New drug could be first to stop deadly fatty liver disease

Scientists at UC San Diego have identified a new drug, ION224, that could transform the treatment of MASH, a dangerous form of fatty liver disease tied to obesity and diabetes. By blocking a key liver enzyme, the drug reduces fat and inflammation, halting the root causes of liver damage. In a year-long clinical trial, patients showed major improvements without serious side effects, offering hope to millions affected worldwide.

Slot DANA? Situs Slot Online Gacor Deposit Qris DANA Pulsa 10k Scatter Hitam

Hi everybody. I’m writing to you because we are reaching an important moment in our reproduction of Harold Katcher’s seminal study of rats rejuvenation, in which we are only 9 months from starting the injections but we raised 71% of the total cost of the experiment. We already published the article of our 2024 experiment in a peer-reviewed journal (https://journals.tmkarpinski.com/index.php/ejbr/article/view/772), in which we injected the Pig Plasma Extracellular Particles (PPEPs) in young rats to assess a potential acute immunogenicity or toxicity — without any negative effect observed. Nina Torres Zanvettor (cofounder of ICR together with me) and I were interviewed some weeks ago by Eleanor Sheekey in her YouTube channel (https://youtu.be/Q-lS1UMHG1o?si=ImDWycjM8r8-KpyF), as we are trying to spread the word about the experiment and the crowdfunding. We are making the experiment in collaboration with Unicamp university and Dr. Marcelo Mori, a world-class aging scientist. The rats are already aging in the university facility and we are preparing the epigenetic age measurements with Horvath’s foundation (Clock Foundation), but we still have to raise 29% (US$21,000) of the total cost (US$75,000).

(https://youtu.be/Q-lS1UMHG1o

We will publish everything (methods, materials and results) immediately, but we need the help of the community too, as we will give back all the information for the community. Could you help us to fund the study? Any amount is important. The link to make a donation is https://www.rejuvenescimento.org/donation. I don’t even consider it precisely a “donation”, but a financial collaboration, as the “donor” would be able to use the information, and maybe they can also use the rejuvenation technology that some day would arise from this research. By the way, if we manage to rejuvenate the rats, we will then try to keep them young as long as we can, in a longevity experiment. Also, if we rejuvenate the rats, we will carry out a safety experiment in a Good Laboratory Practices facility here in Brazil that would allow regulatory approval to try the therapy in human patients who don’t have any other alternative to be kept alive — we expect to be able to carry out those human trials in 2028. So we intend to go all the way to the clinic, if we confirm Katcher’s results.

Slot DANA merupakan bentuk kerja sama situs slot online yang selalu menghadirkan keuntungan besar dalam setiap permainan slot gacor deposit QRIS dana pulsa 10K terbaru bonus scatter hitam.

/* */